HPV Vaccine Deal Gives GSK Royalties From Merck’s Competing Product
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GSK-Merck cross-licensing deal settles human papilloma virus vaccine patent dispute related to separate Phase III vaccine development programs. Merck will pay royalties to GSK